What Prota Therapeutics does

Prota Therapeutics is a late clinical-stage Australian biotechnology company developing PRT120, a proprietary oral immunotherapy (OIT) for the treatment of peanut allergy. The company was founded in 2016 in Melbourne, Australia, and the PRT120 platform is exclusively licensed from the Murdoch Children's Research Institute (MCRI), where it was developed over more than 20 years of research led by Scientific Founder Professor Mimi Tang. The therapy is designed to redirect the peanut-specific immune response from a Th2 allergic phenotype toward tolerance, aiming for sustained unresponsiveness (remission) rather than temporary desensitization, with the goal of allowing patients to consume peanut freely after treatment is discontinued. Clinical evidence includes a 51% remission rate in the PPOIT-003 study, greater than 85% reduction in peanut-specific IgE antibody levels persisting to 12 months post-treatment, and durable tolerance effects confirmed four years after treatment ended in the PPOIT-003LT follow-up.

PRT120 is investigational and not approved for marketing in any region, and the company currently generates no product revenue. Prota's business model is a one-time license-style prescription pharmaceutical model: upon regulatory approval, the product would be sold through standard pharmaceutical distribution channels (wholesale distributors, specialty pharmacies) and prescribed by allergists, immunologists, and pediatricians to patients (primarily children and adults) with diagnosed peanut allergy. The company has raised approximately US$36 million cumulatively, including a US$21 million round led by SPRIM Global Investments in January 2024 earmarked for Phase 3 clinical trials and commercialization preparation. An add-on Digital Allergy Management App accompanies the core therapeutic asset as part of a broader patient-care offering.

Prota's end customers are patients with peanut allergy, approximately 1 in 50 people in the US, and the healthcare providers who treat them. Peanut allergy is the most common cause of life-threatening food-related anaphylaxis and is typically lifelong, with current standard of care limited to avoidance and emergency treatment. Prota addresses this unmet need by pursuing clinical remission rather than lifelong maintenance desensitization. The company is headquartered in Camberwell, Melbourne, and is privately held, with board representation from lead investors OneVentures and SPRIM Global Investments and an experienced leadership team spanning clinical immunology, regulatory affairs, clinical operations, and biotech finance.

Name

Prota Therapeutics

Legal name

Prota Therapeutics Pty Ltd

Website

https://protatherapeutics.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Prota Therapeutics is a late clinical-stage Australian biotech developing PRT120, an investigational oral immunotherapy for peanut allergy that aims to achieve durable remission rather than lifelong desensitization. The product is licensed from Murdoch Children's Research Institute and is preparing for Phase 3 clinical trials.

Ownership category

akta.pro rank

Product category

Allergy Immunotherapy Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• Peanut allergy treatment
• Oral immunotherapy
• Food allergy therapeutics
• Allergen immunotherapy
• Biopharmaceutical development

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Prota Therapeutics' food allergy treatments are investigational and not yet approved for marketing. Once PRT120 receives regulatory approval, the company will generate revenue through prescription pharmaceutical product sales targeting patients with peanut allergy.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Prota Therapeutics is developing PRT120, a proprietary oral immunotherapy for peanut allergy that aims to achieve sustained unresponsiveness (remission) rather than temporary desensitization by redirecting the peanut-specific immune response from allergy toward tolerance. The treatment is investigational and not yet approved for marketing in any region, with a pivotal Phase 3 clinical trial planned. Prota's technology is exclusively licensed from the Murdoch Children's Research Institute in Melbourne, where it was developed over more than 20 years of research led by Professor Mimi Tang.

Product overview

Prota Therapeutics is a late clinical-stage Australian biotech company developing a single proprietary oral immunotherapy product, PRT120, for peanut allergy treatment. The company's technology is based on over two decades of research from Professor Mimi Tang's team at Murdoch Children's Research Institute. PRT120 is a phase-3 ready peanut allergy oral immunotherapy that aims to achieve remission (sustained unresponsiveness) rather than temporary desensitization, allowing patients to freely consume peanut in their diet without ongoing maintenance therapy. The company also developed a digital allergy management app to support patient care alongside the core therapeutic product.

Differentiator

Problem solved

Functional benefit

Products and services

• PRT120 PRT120 is Prota Therapeutics' phase-3 ready proprietary oral immunotherapy treatment for peanut allergy. It is designed to redirect the peanut-specific immune response from the allergy (Th2) pathway towards tolerance, aiming to achieve sustained unresponsiveness (remission) rather than just temporary desensitization. The product is intended to enable patients to consume peanut freely without ongoing maintenance therapy. The product is investigational and is not approved for marketing in any region.

Quantifiable outcome

• 51% peanut allergy remission rate in clinical trials - first company to validate significant quality of life improvements compared with standard care
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Murdoch Children's Research Institute (MCRI)coreTechnology or IntegrationProta's proprietary technology is exclusively licensed from the Murdoch Children's Research Institute in Melbourne, developed over 20+ years of research led by Professor Mimi Tang. This licensing arrangement provides Prota with rights to the PPOIT (Probiotic and Peanut Oral Immunotherapy) technology platform.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Aimmune Therapeutics: Developer of Palforzia (peanut oral immunotherapy), the first FDA-approved peanut allergy OIT. Most directly comparable to Prota in target indication, modality (oral immunotherapy), and patient population; later acquired by Nestlé Health Science. Provides a direct read on regulatory pathway, commercial uptake, and competitive positioning for peanut OIT.
• DBV Technologies: French biotech developing Viaskin Peanut, an epicutaneous immunotherapy patch for peanut allergy in children. Competes in the same peanut allergy space with a different delivery modality (patch vs oral), making it a close comparator for market opportunity and regulatory benchmarks.
• Allergy Therapeutics: UK-based specialty immunotherapy company with a peanut allergy vaccine (VLP Peanut) in clinical development and a broader allergy immunotherapy portfolio. Comparable in modality (allergen-specific immunotherapy) and regulatory pathway; longer commercial track record in allergy.

Emerging players

• Alladapt Immunotherapeutics: US clinical-stage biotech developing ADP101, a multi-food allergen oral immunotherapy targeting peanut plus other common allergens. Comparable in approach (oral immunotherapy) but broader in allergen coverage; useful comp for clinical and regulatory trajectory in food OIT.
• IgGenix: US early-stage biotech developing engineered allergen-specific IgG antibodies for peanut and other food allergies. Represents an emerging next-generation approach (passive immunization) competing with active OIT like PRT120 in the same indication.
• Moonlight Therapeutics: US early-stage biotech developing dissolvable microneedle patches for peanut allergy immunotherapy. Competes in the same indication with a different delivery technology, providing a useful comparator for safety, adherence, and pediatric patient experience versus PRT120 oral therapy.

Broad incumbents

• ALK-Abelló: Danish global leader in allergy immunotherapy with a broad portfolio of subcutaneous and sublingual immunotherapy products across respiratory and food allergens. Serves as a broad incumbent benchmark for commercial infrastructure, payer access, and allergy market dynamics relevant to PRT120's future commercialization.
• Stallergenes Greer: Global specialty biopharmaceutical company focused on allergen immunotherapy, now the parent of Aimmune (Palforzia). Provides both broad-incumbent scale comparison and a relevant reference for commercializing peanut OIT after acquiring the most direct competitor to Prota.
• Sanofi (Dupixent): Global pharmaceutical company whose Dupixent (dupilumab) is being investigated in food allergy (including peanut) and represents a potential competing biologic modality in the same indication. Relevant as both a competitive threat and a potential partnering/acquirer for differentiated food allergy assets like PRT120.
• Regeneron Pharmaceuticals: Co-developer with Sanofi of Dupilumab (Dupixent) which has food allergy programs including in peanut allergy. Relevant broad incumbent for biologic competition in food allergy and as a potential strategic partner or acquirer of differentiated allergy assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prota Therapeutics